How to NavigateConnectDistinguished InvestigatorsConferencesEducationRLT ComponentsSponsorsTrial Stats
Study Title
177Lu-PSMA-617 (Pluvicto) for the Treatment of Patients With Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Super Scan Bone Scan
Study Details
Description:
The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer (mCRPC) and extensive bone metastases, which appear as a "super scan" pattern on a bone scan.
Sponsor:
Ebrahim S Delpassand, MD
Contacts:
Susan Cork (Therapy Coordinator)
scork@exceldiagnostics.com 713-781-6200 ext 3203Nereyda Sauceda (Therapy Coordinator)
nsauceda@exceldiagnostics.com 713-781-6200 ext 3246Government Study Link:
NCT06972628 - Click to see study on ClinicalTrials.gov
Drug Details
Lutetium-177-PSMA-617
Isotope(s):
Target(s):
- PSMA
Chelator: DOTA
Inclusion
Inclusion Criteria Not Yet Provided
Exclusion
Exclusion Criteria Not Yet Provided
